๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Prognostic factors for patients with colon or rectal carcinoma treated with resection only: Five-year follow-up report

โœ Scribed by Takeshi Tominaga; Takashi Sakabe; Yasuo Koyama; Kyoichi Hamano; Masayuki Yasutomi; Takashi Takahashi; Susumu Kodaira; Tomoyuki Kato; Nobuya Ogawa; for the Steering Committee of the Colorectal Cancer Chemotherapy Study Group Japan


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
488 KB
Volume
78
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


BACKGROUND.

The prognostic factors and natural history of recurrence in patients with colorectal carcinoma who underwent curative resection and no other therapy were analyzed. METHODS. The object of analysis was the potentially curative resection only subgroup in the randomized clinical trial (RCT) that we performed. Cox's proportional hazards model was used mainly to analyze recurrence rates during the first 5 years after surgery. RESULTS. The analysis was performed on a subgroup of the RCT (279 patients with colon carcinoma and 293 patients with rectal carcinoma). Five-year disease free survival rates were 76.3% and 56.5% for colon and rectal carcinomas, respectively. The prognostic factors for recurrence for colon carcinoma patients were different from those with rectal carcinoma. For colon carcinoma, only Dukes stage was significant, whereas for rectal carcinoma, Dukes stage, age, location of the tumor, and serosal and venous invasion by cancer cells were prognostic factors. Logtransformed disease free survival rates were linear in Dukes Stage B and biphasic in Dukes Stage C for both colon and rectal carcinoma. The two phases in Dukes Stage C intersected at 2.85 and 3.04 years, respectively. The annual hazard value was high for the first 3 years in both colon and rectal carcinoma. CONCLUSIONS. We conclude that follow-up of patients with colorectal carcinoma who undergo potentially curative resection is of particular importance in the first 3 years after surgery. Furthermore, the usefulness of adjuvant chemotherapy can be adequately evaluated from data yielded during this postoperative period. Cancer


๐Ÿ“œ SIMILAR VOLUMES


The prognostic value of p53 and c-erb b-
โœ Wenche Reed; Einar Hannisdal; Per Johannes Boehler; Stein Gundersen; Herman Host ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 105 KB ๐Ÿ‘ 1 views

## BACKGROUND. Approximately 30% of breast carcinoma patients with negative lymph nodes die of their disease. Biologic markers such p53 protein and c-erb B-2 have been related to tumor progression, but their prognostic value remains controversial. ## METHODS. Two large series of a total of 613 ly